Systemic Inflammation Mediates the Associations Between Abdominal Obesity Indices and Lung Function Decline in a Chinese General Population.

BACKGROUND: Previous studies reported that obesity indices were inversely associated with lung function. However, the underlying mechanisms remain unclear. We aimed to assess the potential mediating effect of systemic inflammation in the associations between obesity indices and lung function decline among a general population.
METHODS: We conducted a cross-sectional study among 3442 participants from the Wuhan-Zhuhai cohort. Plasma C-reactive protein (CRP) was assayed as a marker of systemic inflammation. The relationships among several obesity indices (body mass index, BMI; waist circumference, WC; waist-to-hip ratio, WHR; waist-to-height ratio, WHtR), plasma CRP and lung function were assessed by generalized linear models. The role of CRP in the associations between obesity indices and lung function was analyzed using mediation analysis.
RESULTS: We observed inverse associations between abdominal obesity indices (WC, WHR and WHtR) and lung function parameters, including forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) (all P<0.05). Each 1-unit increase in WC was associated with a 3.39 mL decrease in FEV1 and a 3.96 mL decrease in FVC (all P<0.05). Each 1% increase in WHR and WHtR was associated with a 5.42 mL and a 14.23 mL decrease in FEV1, and a 5.70 mL and a 16.92 mL decrease in FVC (all P<0.05). Mediation analysis indicated that plasma CRP partly mediated the associations between abdominal obesity and lung function. The mediated proportions of CRP in associations of WC, WHR and WHtR with FEV1 were 7.96%, 9.59% and 5.76%, respectively. The mediated proportions of CRP in associations of WC and WHR with FVC were 8.33% and 11.40%, respectively.
CONCLUSION: Abdominal obesity indices were negatively associated with lung function, and the associations may be partly mediated by systemic inflammation.

Background

In 2016, more than 1.95 billion adults worldwide were overweight, and among them over 671 million were obese.1 As a global pandemic, obesity has been demonstrated to reduce the life expectancy and lead to a heavy disease burden.2 Obesity has long been considered as a risk factor for many chronic diseases including respiratory diseases,3,4 cardiovascular diseases,5–7 type 2 diabetes8–10 and liver diseases.11,12 Impaired lung function is an indicator of early respiratory injury and a crucial clinical parameter in the diagnosis of airway dysfunction. Current publications have suggested that obesity, especially abdominal obesity, was associated with impaired lung function.13–15 However, the underlying mechanisms whereby obesity affects the lung function remain unclear.

Systemic inflammation has been reported to be involved in the process of obesity-induced damage and might play a role in the pathogenesis of lung function decline.16,17 C-reactive protein (CRP) is a sensitive marker of low-grade systemic inflammation and a common index in clinical practice. Increasing evidences suggest that some features of metabolic abnormalities such as obesity are risk factors of elevated CRP levels.18,19 On the other hand, systemic inflammation marker CRP has been reported to directly induce lung function decline. One in vitro study showed that CRP existed in the secretions of human respiratory tract,20 and this protein may exert local effects in lung tissue, leading to a subtle reduction in airway diameter and a reduction in lung function. Therefore, we hypothesized that systemic inflammation might mediate and play a part in the associations between obesity indices and declined lung function.

In the present study, we measured the levels of four obesity indices (body mass index, BMI; waist circumference, WC; waist-to-hip ratio, WHR; waist-to-height ratio, WHtR), plasma CRP and lung function in 3442 adults from the Wuhan-Zhuhai cohort in China. The main objectives of this study are: 1) to analyze the associations among obesity indices, plasma CRP and lung function; 2) to assess the mediating role of systemic inflammation presented by plasma CRP in the associations between obesity indices and declined lung function.

Methods

Study Design and Population

The study participants were originated from the baseline survey of Wuhan-Zhuhai cohort, which has been described previously.24 Briefly, this community-based prospective cohort was established between 2011 and 2012, including 4812 individuals aged 18–80 years who had lived in Wuhan or Zhuhai city for more than 5 years. Each participant underwent standardized questionnaires and physical examination on the same day. We excluded 1370 participants who had physician-diagnosed respiratory diseases, or who failed to conduct anthropometry, lung function or plasma CRP. A total of 3442 subjects were ultimately included. Individuals included and excluded in our study showed no differences with respect to basic demographic characteristics such as body mass index, smoking status, drinking status, education levels, etc. (P>0.05). All participants in the study signed written informed consent. The study was approved by the Ethics and Human Subject Committee of Tongji Medical College, Huazhong University of Science and Technology (No. 2011-17).

Anthropometry

Standing height (cm) and body weight (kg) were measured in light clothing and no shoes, using the weighing scale with a vertically fixed ruler (RGZ-120, China). BMI was calculated as the weight in kilograms divided by the square of the height in meters. WC was measured midway between the lower costal margin and the iliac crest using a horizontally placed tape, and hip circumference at the maximum circumference of the buttocks. WHR was calculated as the WC in centimeters divided by the hip circumference in centimeters, while WHtR was calculated as the WC in centimeters divided by the height in centimeters. Abdominal obesity was defined as follows: WC ≥90 cm in men and ≥85 cm in women.25

Lung Function Test

Lung function tests including forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC) and the ratio of FEV1 to FVC (FEV1/FVC) were performed with a digital spirometer (Chestgraph HI-101, CHEST MI, Inc., Tokyo, Japan), based on the American Thoracic Society Recommendations.26 The spirometry devices were calibrated each morning before testing, according to the manufacturer’s instruction. Each participant was required to keep a sitting position, wear a nose clip and breathe through the blowing nozzle. Three satisfactory volume–time curves were performed for each participant, and the highest value of FEV1 or FVC was used in the analyses.

Plasma CRP Measurements

Venous blood sample was collected from each participant after a 12-h fast at baseline examination and kept frozen at −80°C until being thawed for CRP analysis. Plasma CRP was determined with a commercially available enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, MN, USA) according to manufacturer’s instructions, with the range of 15.6–1000 pg/mL. All the samples were replicated two times.

Definitions of Covariates

Information on sociodemographic characteristics (gender, age, city, and family income), occupational hazard exposure (industrial dust, noise, tobacco smoking, cooking or heating in the winter), lifestyles (smoking status, drinking status, regular physical activity and cooking meals at home), drug status and chronic diseases history was collected through questionnaires by face-to-face interviews with trained interviewers. Individuals who had been smoking at least one cigarette per day for more than half a year were defined as current smokers, and those who had been drinking alcohol at least one time per week for more than half a year were defined as current drinkers. Smoking status was assessed as smokers (current and former smokers) and nonsmokers. Drinking status was assessed as drinkers (current and former drinkers) and nondrinkers. Regular physical activity was defined as regular exercise at least twice a week for more than 20 min each time over the last 6 months. Drug status was assessed by asking “Did you take any medication (antilipemic agent, antihypertensive drug, oral antidiabetic agents, insulin, paregoric, aspirin, antibiotic, asthma drugs and so on) over the past 2 weeks”.

Statistical Analysis

For continuous analyses, plasma CRP was log-transformed due to its right-skewed distribution. For categorical analyses, participants were divided into four groups according to the quartiles of CRP levels. The baseline characteristics of the groups were compared using analysis of variance for continuous variables and using Chi-square test for categorical variables.

Both continuous and categorical analyses were conducted to quantify the associations among obesity indices, CRP concentration and lung function parameters (FEV1, FVC and FEV1/FVC) by generalized linear models with adjustment for potential confounders, including gender, age, city, occupational hazard exposure, drug status, smoking status, drinking status, regular physical activity, cooking meals at home, and family income. Stratified analyses were conducted to investigate whether gender and smoking status modified the associations among obesity indices, plasma CRP and lung function in separate generalized linear models, without adjusting for the stratification variable. Effect modification was tested by including an interaction term of obesity indices or plasma CRP multiplied by gender or smoking status in the generalized linear models. We further divided smokers into groups of non-abdominal obesity and abdominal obesity, the associations between obesity indices and lung function were analyzed by generalized linear model in each subgroup.

To assess the mediating role of CRP in the associations between obesity indices and lung function, we conducted mediation analyses by using MEDIATION macro described by Valeri L and VanderWeele T J.27 We first assessed the joint effect of obesity indices and plasma CRP on lung function by including an interaction term of obesity indices multiplied by plasma CRP in the generalized linear models. If there was no joint effect, we then ran the mediation macro with the correctly specified outcome regression model without the exposure–mediator interaction term. If there is a joint effect, we included the exposure–mediator interaction term into the model. We also calculated the proportion mediated as follows: Proportion mediated= Mediated effect/Total effect×100%. All tests were two-sided with a significant level at 0.05, and all statistical analyses were conducted using SAS 9.4 software (SAS Institute Inc., Cary, NC, USA).

Results

Basic Characteristics

The characteristics of the 3442 subjects according to the quartiles of plasma CRP are displayed in Table 1. The mean age of all participants (1087 men; 31.58%) was 52.77 (12.76) years. The median, lower and upper quartile of plasma CRP concentration were estimated at 0.581 and (0.226 to 1.381) mg/l. Participants with higher plasma CRP levels tended to be older and smokers, had a higher BMI, WC, WHR and WHtR, had lower FEV1 and FVC, were less likely to be physically active and were more likely to cooking meals at home.

Table 1

Basic Characteristics of Participants by Quartile of Plasma CRP Levels (N=3442)

Characteristics	All Participants	Quartile of Plasma CRP Level, mg/l				P value
≤0.226	0.226–0.581	0.581–1.381	>1.381
No. of participant	3442	860	861	860	861
Male, n (%)	1087 (31.58)	270 (31.40)	264 (30.66)	285 (33.14)	268 (31.13)	0.8138
Age, years (mean ±SD)	52.77±12.76	48.12±13.54	52.16±12.13	54.87±12.36	55.92±11.51	<0.0001
Family income ≥40,000 RMB/year, n (%)	1451 (42.16)	381 (44.30)	358 (41.58)	379 (44.07)	333 (38.68)	0.0559
Regular physical activity, n (%)	1808 (42.16)	486 (56.51)	460 (53.43)	432 (50.23)	430 (49.94)	0.0062
Cooking meals at home, n (%)	2547 (74.00)	613 (71.28)	632 (73.40)	638 (74.19)	664 (77.12)	0.0062
Occupational hazard expose/yes, n (%)	1024 (29.75)	243 (28.26)	261 (30.31)	253 (29.42)	267 (31.01)	0.6252
Drug status/yes, n (%)	1513 (43.96)	314 36.51)	345 (40.07)	409 (47.56)	445 (51.68)	<0.0001
Smoking status						0.0081
Smokers	724 (21.03)	156 (18.14)	174 (20.20)	199 (23.14)	195 (22.65)
Nonsmokers	2718 (78.97)	704 (81.86)	687 (79.79)	661 (78.86)	666 (77.35)
Drinking status						0.1067
Drinkers	579 (16.82)	131(15.23)	154 (17.89)	162 (18.84)	132 (15.33)
Nondrinkers	2863 (83.18)	729 (84.77)	707 (82.11)	698 (81.16)	729 (84.67)
BMI, kg/m2 (mean ± SD)	24.00±3.43	22.45±3.04	23.68±3.04	24.58±3.37	25.29±3.57	<0.0001
WC, cm (mean ±SD)	81.35±11.59	76.29±11.69	81.03±9.51	83.49±11.13	84.59±12.08	<0.0001
WHR (mean ±SD)	0.87±0.07	0.84±0.06	0.87±0.07	0.88±0.07	0.89±0.06	<0.0001
WHtR (mean ±SD)	0.51±0.07	0.48±0.07	0.51±0.06	0.53±0.07	0.54±0.08	<0.0001
FEV1, mL (mean ±SD)	2179.60±597.82	2312.21±602.81	2205.11±606.34	2146.74±601.43	2054.47±550.53	<0.0001
FVC, mL(mean ±SD)	2500.30±689.98	2631.98±691.05	2551.10±691.55	2445.35±702.34	2372.47±646.20	<0.0001
FEV1/FVC (mean ±SD)	87.63±8.46	88.44±8.42	86.93±8.48	88.09±8.31	87.04±8.56	0.0001

Abbreviations: CRP, C-reactive protein; SD, standard deviation; BMI, Body mass index; WC, Waist circumference; WHR, Waist-to-hip ratio; WHtR, Waist-to-height ratio; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.

Associations Between Obesity Indices and Lung Function Alteration

The associations between obesity indices and lung function alteration are presented in Table 2. After adjusting for potential confounders, abdominal obesity indices including WC, WHR, and WHtR were negatively associated with FEV1 and FVC. In the continuous analyses, each 1-unit increase in WC was associated with a 3.39 mL decrease in FEV1 and a 3.96 mL decrease in FVC (all P<0.05). Each 1% increase in WHR and WHtR was associated with a 5.42 mL and a 14.23 mL decrease in FEV1, and a 5.70 mL and a 16.92 mL decrease in FVC, respectively (all P<0.05). No significant association was observed between BMI and FEV1 or FVC. In the categorical analyses, we found significantly monotonic FEV1 and FVC declines with gradually increasing WC, WHR or WHtR (all P for trend <0.05). While, FEV1/FVC was not related to obesity indices in neither continuous analyses nor categorical analyses.

Table 2

Association Between Obesity Indices and Lung Function Parameters (N = 3442)

Parameter	Estimated Changes (mL) (95% CI) by Continuous Obesity Indices	Estimated Changes in mL (95% CI) by Obesity Indices				P value for Trend
Q1	Q2	Q3	Q4
BMI*		≤21.63	21.63–23.76	23.76–26.09	>26.09
FEV1	1.27 (−3.03,5.58)	0 (ref)	17.21 (−24.11,58.53)	71.07 (29.53,112.62)	17.37 (−24.32,59.07)	0.1208
FVC	−1.15 (−6.24,3.95)	0 (ref)	15.30 (−33.64,64.23)	57.84 (8.64,107.04)	−4.75 (−54.13,44.63)	0.7374
FEV1/FVC	0.06 (−0.02,0.14)	0 (ref)	0.20 (−0.58,0.98)	0.42 (−0.36,1.21)	0.62 (−0.16,1.41)	0.0991
WC†		≤74.90	74.90–81.60	81.60–88.20	>88.20
FEV1	−3.39 (−5.16,-1.63)	0 (ref)	14.30 (−27.79,56.39)	−24.51 (−73.28,24.25)	−99.27 (−163.39,-35.15)	0.0030
FVC	−3.96 (−6.06,-1.87)	0 (ref)	8.57 (−41.39,58.52)	−23.94 (−81.82,33.95)	−114.37 (−191.48,-38.25)	0.0058
FEV1/FVC	0.01 (−0.03,0.04)	0 (ref)	−0.10 (−0.93,0.74)	0.01 (−0.96,0.99)	0.02 (−1.26,1.30)	0.9308
WHR*100†		≤82.06	82.06–86.77	86.77–91.54	>91.54
FEV1	−5.42 (−8.04,-2.81)	0 (ref)	−35.56 (−76.00,4.89)	−41.68 (−85.29,1.92)	−107.93 (−156.07,-59.80)	<0.0001
FVC	−5.70 (−8.81,-2.60)	0 (ref)	−29.24 (−77.27,18.78)	−41.95 (−93.72,9.83)	−111.01 (−168.16,-54.86)	0.0002
FEV1/FVC	−0.01(−0.06,0.05)	0 (ref)	0.01 (−0.80,0.82)	0.06 (−0.81,0.92)	−0.07(−1.03,0.89)	0.9158
WHtR*100‡		≤47.17	47.17–51.25	51.25–55.52	>55.52
FEV1	−14.23 (−16.71,-11.75)	0 (ref)	−77.05 (−118.70,-35.39)	−182.74 (−228.55,-136.93)	−353.25 (−406.58,-299.92)	<0.0001
FVC	−16.92 (−19.86,-13.98)	0 (ref)	−104.36 (−153.72,-55.01)	−223.99 (−278.26,-169.72)	−434.46 (−497.65,-371.28)	<0.0001
FEV1/FVC	0.02 (−0.03,0.07)	0 (ref)	0.28 (−0.53,1.10)	0.51 (−0.39,1.41)	0.67 (−0.38,1.71)	0.1933

Notes: *Models were adjusted for gender (male/female), age (continuous), city (Wuhan/Zhuhai), occupational hazard exposure (yes/no), drug status (yes/no), smoking status (smokers/nonsmokers), drinking status (drinkers/nondrinkers), regular physical activity (yes/no), cooking meals at home (yes/no), and family income (≥40,000/<40,000 RMB/year). †Models were adjusted for *models plus height, and weight. ‡Models were adjusted for *models plus weight.

Abbreviations: BMI, Body mass index; WC, Waist circumference; WHR, Waist-to-hip ratio; WHtR, Waist-to-height ratio; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.

Stratified analyses suggested that gender and smoking status modified the negative associations between obesity indices and lung function. The associations between obesity indices and lung function decline among males, females and non-smokers were consistent with those from the primary analyses. While among smokers, the associations between WC and FEV1 and the association between WC or WHR and FVC were out of significance (). We further divided the smokers into groups of non-abdominal obesity and abdominal obesity, and the results showed that the obesity indices in the abdominal obesity group led to a larger decline in lung function ().

Associations Between Obesity Indices and CRP Concentration

The associations between obesity indices and CRP concentration are shown in Table 3. Each 1-unit increase in BMI or WC was associated with 0.048 and 0.005 increase in log-transformed CRP concentration (P<0.05). Each 1% increase in WHR or WHtR was associated with 0.010 and 0.012 increase in plasma CRP, respectively (all P<0.05). In the categorical analyses, the CRP concentration was significantly and monotonously increased with increasing quartiles of BMI, WC, WHR and WHtR (all P for trend <0.05). Stratified analyses showed that the associations between obesity indices and CRP concentration remained stable among males, females, smokers and non-smokers ().

Table 3

Associations Between Obesity Indices and CRP (N = 3442)

Obesity Indices	Estimated Changes mg/l (95% CI) by Continuous Obesity Indices	Estimated Changes in mg/l(95% CI) by Obesity Indices				P value for Trend
Q1	Q2	Q3	Q4
BMI*		≤21.63	21.63–23.76	23.76–26.09	>26.09
	0.048 (0.042,0.054)	0 (ref)	0.124 (0.068,0.180)	0.246 (0.190,0.302)	0.418 (0.362,0.475)	<0.0001
WC†		≤74.90	74.90–81.60	81.60–88.20	>88.20
	0.005 (0.002,0.007)	0 (ref)	0.039 (−0.021,0.099)	0.136 (0.066,0.205)	0.185 (0.094,0.276)	<0.0001
WHR*100†		≤82.06	82.06–86.77	86.77–91.54	>91.54
	0.010 (0.006,0.013)	0 (ref)	0.104 (0.046,0.153)	0.091 (0.029,0.153)	0.158 (0.090,0.227)	<0.0001
WHtR*100‡		≤47.17	47.17–51.25	51.25–55.52	>55.52
	0.012 (0.009,0.016)	0 (ref)	0.080 (0.021,0.137)	0.199 (0.135,0.263)	0.282 (0.207,0.357)	<0.0001

Notes: *Models were adjusted for gender (male/female), age (continuous), city (Wuhan/Zhuhai), occupational hazard exposure (yes/no), drug status (yes/no), smoking status (smokers/nonsmokers), drinking status (drinkers/nondrinkers), regular physical activity (yes/no), cooking meals at home (yes/no), and family income (≥40,000/<40,000 RMB/year). †Models were adjusted for *models plus height (continuous), and weight (continuous). ‡Models were adjusted for *models plus weight (continuous).

Abbreviations: CRP, C-reactive protein; BMI, Body mass index; WC, Waist circumference; WHR, Waist-to-hip ratio; WHtR, Waist-to-height ratio.

Association Between CRP Concentration and Lung Function Alteration

Table 4 presents the association between CRP concentration and lung function alteration. Results from the continuous analyses showed that each 1-unit increase in the log-transformed concentration of CRP was associated with a 58.25 mL and 71.64 mL decrease in FEV1 and FVC, respectively. In the categorical analyses, we found significantly monotonic FEV1 and FVC declines with increasing CRP. No significant association was found between plasma CRP and FEV1/FVC. After performing stratified analyses, the findings among males, females, non-smokers were consistent with those from the primary analysis. While among smokers, no significant associations between CRP with FEV1 and FVC were observed anymore ().

Table 4

Associations Between CRP and Lung Function Parameters (N = 3442)

Lung Function Parameters	Estimated Changes (mL) (95% CI) by Continuous CRP*	Estimated Changes in mL (95% CI) by Quartile of Plasma CRP Level†				P value for Trend
≤0.226	0.226–0.581	0.581–1.381	>1.381
FEV1	−58.25 (−81.74,-34.76)	0 (ref)	−38.12 (−77.45, 1.22)	−42.26 (−82.64,-1.87)	−104.52 (−145.88,-63.15)	<0.0001
FVC	−71.64 (−99.51,-43.78)	0 (ref)	−19.27 (−65.95,27.41)	−62.13 (−110.06,-14.21)	−113.91 (−163.00,-64.82)	<0.0001
FEV1/FVC	0.20 (−0.27,0.67)	0 (ref)	−0.80 (−1.58,-0.01)	0.31 (−0.49,1.12)	−0.20 (−1.03,0.62)	0.6920

Notes: *Log-transformed CRP. †Models were adjusted for gender (male/female), age (continuous), height (continuous), weight (continuous), city (Wuhan/Zhuhai), occupational hazard exposure (yes/no), drug status (yes/no), smoking status (smokers/nonsmokers), drinking status (drinkers/nondrinkers), regular physical activity (yes/no), cooking meals at home (yes/no), and family income (≥40,000/<40,000 RMB/year).

Abbreviations: CRP, C-reactive protein; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.

Role of Plasma CRP in the Associations Between Obesity Indices and Lung Function

We assessed both joint effect and mediated effect of plasma CRP in the associations between abdominal obesity indices and lung function (Tables 5 and 6). Table 5 shows that WHtR and plasma CRP had a joint effect on FVC (P<0.05), other multiplicative interactions were not significant (P>0.05). Table 6 shows the total effect, direct effect of abdominal obesity indices on FEV1 and FVC and mediation assessment on plasma CRP. We observed the mediated proportions of plasma CRP in associations of WC, WHR and WHtR with FEV1 were 7.96%, 9.59% and 5.76%, respectively. The mediated proportions of plasma CRP in associations of WC and WHR with FVC were 8.33%, 11.40%, respectively. We did not find the mediated effect of plasma CRP in the associations between WHtR and FVC.

Table 5

Joint Effect of Abdominal Obesity Indices and Plasma CRP on FEV1 and FVC (N=3442)

Parameter	Estimated Changes (mL) (95% CI) by Continuous Obesity Indices	P for Interaction
WC*logCRP†
FEV1	−0.58(−2.31,1.16)	0.5146
FVC	−1.53 (−3.59,0.53)	0.1446
(WHR*100)*logCRP†
FEV1	−1.28 (−4.57,2.02)	0.4486
FVC	−3.89 (−7.80,0.02)	0.0511
(WHtR*100)*logCRP‡
FEV1	−2.62 (−5.48,0.23)	0.0720
FVC	−4.37 (−7.76,-0.99)	0.0114

Notes: †Models were adjusted for gender (male/female), age (continuous), height (continuous), weight (continuous), city (Wuhan/Zhuhai), occupational hazard exposure (yes/no), drug status (yes/no), smoking status (smokers/nonsmokers), drinking status (drinkers/nondrinkers), regular physical activity (yes/no), cooking meals at home (yes/no), and family income (≥40,000/<40,000 RMB/year). ‡Models were adjusted for †models without height (continuous).

Abbreviations: CRP, C-reactive protein; WC, Waist circumference; WHR, Waist-to-hip ratio; WHtR, Waist-to-height ratio; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.

Table 6

Mediating Effects of Plasma CRP Level on Associations Between Abdominal Obesity Indices and FEV1 and FVC (N = 3442)

Parameters	Total Effect	Mediated Effect	Direct Effect	Proportion Mediated (%)
FEV1
WC†	−3.39 (−5.16,-1.63)	−0.27 (−0.45,-0.09)	−3.12 (−4.88,-1.36)	7.96
WHR*100†	−5.42 (−8.04,-2.81)	−0.52 (−0.82,-0.22)	−4.90 (−7.52,-2.29)	9.59
WHtR*100‡	−14.23 (−16.71,-11.75)	−0.82 (−1.19,-0.45)	−13.41 (−15.89,-10.92)	5.76
FVC
WC	−3.96 (−6.06,-1.87)	−0.34 (−0.56,-0.12)	−3.63 (−5.72,-1.53)	8.33
WHR*100	−5.70 (−8.81,-2.60)	−0.65 (−1.01,-0.28)	−5.05 (−8.16,-1.95)	11.40
WHtR*100	−11.46 (−16.74,-6.18)	1.65 (−0.48,3.79)	−13.12 (−0.48,-9.38)	-

Notes: †Models were adjusted for gender (male/female), age (continuous), height (continuous), weight (continuous), city (Wuhan/Zhuhai), occupational hazard exposure (yes/no), drug status (yes/no), smoking status (smokers/nonsmokers), drinking status (drinkers/nondrinkers), regular physical activity (yes/no), cooking meals at home (yes/no), and family income (≥40,000/<40,000 RMB/year). ‡Models were adjusted for †models without height (continuous).

Abbreviations: CRP, C-reactive protein; WC, Waist circumference; WHR, Waist-to-hip ratio; WHtR, Waist-to-height ratio; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.

Discussion

In the present study, we observed that abdominal obesity indices (WC, WHR and WHtR) were negatively associated with FEV1 and FVC after adjusting for potential confounders in a general population in China. We also observed significantly positive associations between all obesity indices and plasma CRP and significantly negative associations between plasma CRP and lung function parameters (FEV1 and FVC). Plasma CRP may serve as a mediator in the associations of abdominal obesity indices (WC, WHR and WHtR) with decreased lung function. However, we did not find the significant association between BMI and lung function. The results of the previous studies regarding the association between BMI and FEV1 or FVC were inconclusive.13,28–32 A cross-sectional study based on the British community did not find a linear association between BMI and FEV1 or FVC among 2633 adults, which was in accordance with our results.30 However, a cross-sectional study conducted in Mediterranean smokers found that BMI was inversely associated with lung function.31 Moreover, the National Health and Nutrition Examination Survey (NHANES III) reported an inverted U-shaped relationship between BMI and FEV1 and FVC.32 Such discrepancy may be due to differences in the ethnic group, heredity, and cigarette smoking.

Published studies14,15,28,29 have suggested that abdominal obesity was associated with impaired lung function, which was similar to our results. Although BMI is accepted worldwide as an important index of obesity, it fails to distinguish the fat mass from fat-free mass or to represent the pattern of fat distribution. With the measurement of WC, WHR and WHtR, we were able to examine the association between the distribution of body fat and lung function, and the results suggested that abdominal obesity was strongly associated with FEV1 and FVC reductions. These results indicated that abdominal obesity indices may better reflect the effect of obesity on lung function.

Previous studies have shown that obesity was associated with systemic inflammation levels, while plasma CRP is the most commonly used marker of systemic inflammation. Among a general population in Taiwan area, obesity indices including BMI, WC and WHtR were significantly associated with elevated CRP levels in women.33 A study of 2589 individuals from Inner Mongolia in China found that WC was positively associated with the elevated risk of inflammation independently of BMI.34 Our results showed that both general (BMI) and abdominal obesity indices (WC, WHR and WHtR) were significantly and positively associated with plasma CRP in general adults. To exclude the potential confounding effects of cigarette smoking, which can cause the increase of plasma CRP,35 we further separately evaluated the relationships between obesity indices and CRP levels among smokers and non-smokers. We found that the associations remained stable in both subgroups. These results suggested that the positive relationships between obesity indices and CRP occurred independently of cigarette smoking.

The inverse association between CRP and lung function has been reported in several studies.21–23,36 Aronson and his colleagues found inverse linear relationships between CRP concentrations and lung function in subjects without pulmonary disease and in never-smokers.22 A recent cross-sectional study showed that higher CRP concentration was associated with the lower lung volume.36 A 13-year follow-up study showed that lung function and CRP were inversely interrelated.23 Similarly, we found inverse associations between plasma CRP and FEV1 and FVC.

A cross-sectional study conducted in Korea reported the combined effects of body fat and CRP with pulmonary dysfunction.37 Similarly, we found a combined effect of WHtR and CRP on FVC. Furthermore, we performed a mediation analysis and innovatively found a mediating role for CRP in the association between abdominal obesity and decreased lung function. Numerous studies indicated that systemic inflammation occurred as a consequence of abdominal obesity, and recent insights suggested that CRP might play an important role in altered lung function. Abdominal adiposity led to distinct metabolic abnormalities such as increased levels of free fatty acid,38 which could trigger the release of CRP.17 On the other hand, the chronic systemic inflammation from obesity may enhance telomere shortening, which in turn leads to senescence of lung alveolar endothelial cells.39,40 Endothelial dysfunction induced by systemic inflammation41 may lead to pulmonary vascular filtration and lung tissue damage. These processes resulted in a comprehensive effect on pulmonary impairment. In the present study, plasma CRP mediated the associations of abdominal obesity indices with lung function reduction. It provides the basis for further mechanism study on this topic.

Some studies showed that gender modified the effect of obesity on lung function.13,42 In our analyses, the inverse associations between abdominal obesity indices with FEV1 and FVC were significant in both men and women, though it tended to be weaker in women than in men. One possible explanation for the difference might be sex-based differences in lifestyle, hormonal system, body fat distribution, and pulmonary structure. To assess the impact of smoking on the relationships between obesity indices and lung function, we further evaluated the relationships in both smokers and non-smokers. Among non-smokers, we found inverse associations between abdominal obesity indices with lung function. However, such associations were no longer significant among cigarette smokers. Further subgroup analyses in smokers showed that smokers with abdominal obesity had a more evident obesity indices-associated lung function decline, compared with those without abdominal obesity. The possible reason might be that smoking covered the impact of obesity on lung function.

Our study has several strengths. First, the study was conducted among a relatively large population. Second, we measured individual plasma CRP and collected detailed personal life habit information data. Third, we identified a mediating role of systemic inflammation in the associations between abdominal obesity indices and lung function decline, which might contribute to the understanding of potential mechanisms. There are also some limitations in our study. First, we did not measure body fat directly. Second, this was a cross-sectional study which did not reveal a causal relationship. Further longitudinal study would help to confirm the causal links among obesity indices, plasma CRP and lung function.

Conclusions

In this study, we found that abdominal obesity indices (WC, WHR and WHtR) were significantly and negatively associated with plasma CRP and FEV1 and FVC. Systemic inflammation may serve as a mediator in the associations of abdominal obesity indices (WC, WHR and WHtR) with decreased FEV1 and FVC.